We employed BTZ-sensitive and -resistant ALL and AML in vitro cell line models and primary ALL and AML clinical specimens to compare the mechanism of action and anti-leukemic activity of IXA vs. BTZ. This evidence concerns the gene CASC3 and acute myeloid leukemia.